OncoMethylome Sciences Successfully Completes Private Share Offering Raising €10.6 million


Liege (Belgium) - October 16, 2007, 14:45 CET - OncoMethylome OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces that it has raised €10.6 million through a private placement to institutional and qualified investors.
 
The accelerated bookbuild offering announced this morning has allowed OncoMethylome to place 1,063,351 new shares with institutional and qualified investors at a price of €10.00 per share, raising €10.6 million.
 
The share offering was more than two times oversubscribed due to interest from a large number of high-quality European institutional investors.
 
Subject to certain conditions that are standard for this type of transaction, the shares will be issued and paid for on October 19, 2007. The Company will apply for admission of the shares on Eurolist by Euronext Brussels and Euronext Amsterdam.
 
Commenting on today's offering, Herman Spolders, CEO of OncoMethylome, said: "I am very pleased that we have secured this additional funding which reinforces our financial position and will support our product development and clinical trials. The funds were raised from a broad range of institutional investors thus further strengthening our shareholder base and share liquidity."
 
The shares were placed by Piper Jaffray Ltd., Kempen & Co and ING Belgium.
 
About OncoMethylome Sciences
OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
 
OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Millipore Corporation's BioScience Division, and EXACT Sciences Corp.  OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).   
 
Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
 
For more information please contact:
Lucija Turcinov
Tel. +32-479-801-902
 

Attachments

Press Release PDF